Skip to main content
Log in

Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012

  • Systematic Review
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background

Allopurinol is the primary therapy for the management of chronic gout. Utilization of allopurinol has increased in tandem with the growing prevalence of gout globally. This exposes more patients to the risk of allopurinol hypersensitivity (AH), a rare adverse reaction characterised by a spectrum of cutaneous reactions and systemic manifestations. Severe forms of AH have been associated with high mortality. The pathophysiology underlying this reaction remains unknown, but several risk factors have been proposed.

Objective

The aim of this study was to review all published cases of AH documented in the literature in order to better understand the constellation of factors predisposing to this reaction, building on previous reviews by Lupton and Odom [163], Singer and Wallace [8]) and Arellano and Sacristan [9]).

Methods

A literature search was conducted in MEDLINE and EMBASE to identify relevant articles published between January 1950 and December 2012, with no language restrictions imposed. Articles that were included reported either allopurinol-induced cutaneous manifestations alone or satisfied the diagnostic criteria for AH as defined by Singer and Wallace.

Results

Nine hundred and one patients (overall AH cohort) were identified from 320 publications. Of these patients, 802 satisfied the Singer and Wallace criteria (‘Singer and Wallace’ cohort) while 99 patients had only mild cutaneous manifestations (‘non-Singer and Wallace’ cohort). Data were often incomplete; hence the results reported reflect the fractions of the subsets of the cohort where the data in question were available. In the overall AH cohort, 58 % (416/722) were male. The majority (73 %; 430/590) of patients were Asian. Renal impairment (48 %; 182/376) and hypertension (42 %; 160/376) were the most common chronic conditions; accordingly, diuretics (45 %; 114/252) and antihypertensives (39 %; 99/252) were the most prevalent concomitant medications. Allopurinol was prescribed for approved indications (chronic gout and chemoprophylaxis) in only 40 % (186/464) of patients. The median allopurinol dose was 300 mg/day (range 10–1,000 mg/day) and was taken by 50 % (168/338). There was no significant association between a higher dose (>300 mg/day) and an increased risk of severe cutaneous manifestations [odds ratio (OR) 1.76; 95 % CI 0.73–4.22; p = 0.23]. Approximately 90 % (489/538) of patients developed AH within 60 days of initiating allopurinol therapy. Serum oxypurinol (the active metabolite of allopurinol) concentration was only recorded in six patients, four of whom had levels within the putative therapeutic range of 30–100 μmol/L. The HLA-B*5801 allele was present in 99 % (166/167) of patients tested, with the majority (147/166) being of Asian ancestry. The all-cause mortality rate was 14 % (109/788) with 94 AH-related deaths, all of which occurred in the cohort meeting the Singer and Wallace criteria.

Limitations

The publications included in this review utilized different laboratory reference ranges to classify the non-cutaneous manifestations of AH; this may have introduced some variation in the cases identified as AH. A majority of the articles included in this analysis consisted of case reports and series—publication types that are not recognized as best-quality evidence; this thus limited the conclusions we could draw about the many risk factors we were interested in evaluating.

Conclusions

Risk factors associated with AH, such as concomitant diuretic use, pre-existing renal impairment and recent initiation of allopurinol, were commonly present in AH patients; however, their role in the mechanism of AH remains to be established. A clear risk factor was the HLA-B*5801 status; this was especially relevant in Asian populations where there is a higher carriage rate of the allele. High allopurinol dose, previously suggested to be a risk factor, was not confirmed as such. The paucity of well-documented case reports and studies of AH render it difficult to draw more concrete conclusions or construct a meticulous profile of patients at risk of AH. Future case reports of AH need to be better documented to contribute to understanding the risks for, and mechanisms of, AH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64:229–58.

    Article  PubMed  CAS  Google Scholar 

  2. Bradlow A. Adverse reactions profile: allopurinol. Prescr J. 1997;37:29–33.

    Google Scholar 

  3. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87–114.

    Article  PubMed  CAS  Google Scholar 

  4. Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46:623–44.

    Article  PubMed  CAS  Google Scholar 

  5. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981;40:245–9.

    Article  PubMed  CAS  Google Scholar 

  6. Aubock J, Fritsch P. Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. BMJ. 1985;290:1969–70.

    Article  PubMed  CAS  Google Scholar 

  7. Lang PG Jr. Severe hypersensitivity reactions to allopurinol. South Med J. 1979;72:1361–8.

    Article  PubMed  Google Scholar 

  8. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum. 1986;29:82–7.

    Article  PubMed  CAS  Google Scholar 

  9. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337–43.

    PubMed  CAS  Google Scholar 

  10. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20:391–5.

    Article  PubMed  Google Scholar 

  11. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47–56.

    Article  PubMed  CAS  Google Scholar 

  12. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:135–40.

    Article  PubMed  CAS  Google Scholar 

  13. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529–36.

    Article  PubMed  CAS  Google Scholar 

  14. Chang HY, Pan WH, Yeh WT, et al. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993–96). J Rheumatol. 2001;28:1640–6.

    PubMed  CAS  Google Scholar 

  15. Minaur N, Sawyers S, Parker J, et al. Rheumatic disease in an Australian Aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol. 2004;31:965–72.

    PubMed  Google Scholar 

  16. Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther. 2008;10:R17.

    Article  PubMed  Google Scholar 

  17. Anagnostopoulos I, Zinzaras E, Alexiou I, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord. 2010;11:98.

    Article  PubMed  Google Scholar 

  18. Cea Soriano L, Rothenbacher D, Choi HK, et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011;13:R39.

    Article  PubMed  Google Scholar 

  19. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.

    Article  PubMed  Google Scholar 

  20. Robinson PC, Taylor WJ, Merriman TR. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern Med J. 2012;42:997–1007.

    Google Scholar 

  21. Winnard D, Wright C, Taylor WJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford). 2012;51:901–9.

    Article  Google Scholar 

  22. Zineh I, Mummaneni P, Lyndly J, et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics. 2011;12:1741–9.

    Article  PubMed  CAS  Google Scholar 

  23. Chung Y, Lu CY, Graham GG, et al. Utilization of allopurinol in the Australian community. Intern Med J. 2008;38:388–95.

    Article  PubMed  CAS  Google Scholar 

  24. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25–32.

    Article  PubMed  Google Scholar 

  25. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44.

    Article  PubMed  CAS  Google Scholar 

  26. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.

    Article  PubMed  Google Scholar 

  27. Klinenberg JR. The effectiveness of allopurinol in the treatment of gout. Arthritis Rheum. 1965;8:891–5.

    Article  PubMed  CAS  Google Scholar 

  28. Scott JT, Hall AP, Grahame R. Allopurinol in treatment of gout. Br Med J. 1966;2:321–7.

    Article  PubMed  CAS  Google Scholar 

  29. Blechman WJ, Rosenberg DG, Hilf P. Use of allopurinol in gout, hyperuricemia and uric acid lithiasis. South Med J. 1967;60:215–8.

    Article  PubMed  CAS  Google Scholar 

  30. Muggia FM, Ball TJ Jr, Ultmann JE. Allopurinol in the treatment of neoplastic disease complicated by hyperuricemia. Arch Intern Med. 1967;120:12–8.

    Article  PubMed  CAS  Google Scholar 

  31. Wilson JD, Simmonds HA, North JD. Allopurinol in the treatment of uraemic patients with gout. Ann Rheum Dis. 1967;26:136–42.

    Article  PubMed  CAS  Google Scholar 

  32. Manahan LA, Portes JC. Allopurinol in the treatment of gout. Acta Medica Philipp. 1968;4:189–97.

    Google Scholar 

  33. Kantor GL. Toxic epidermal necrolysis, azotemia, and death after allopurinol therapy. JAMA. 1970;212:478–9.

    Article  PubMed  CAS  Google Scholar 

  34. Bailey RR, Neale TJ, Lynn KL. Allopurinol-associated arteritis. Lancet. 1976;2:907.

    Article  PubMed  CAS  Google Scholar 

  35. Espiritu CR, Alalu J, Glueckauf LG, et al. Allopurinol-induced granulomatous hepatitis. Am J Dig Dis. 1976;21:804–6.

    Article  PubMed  CAS  Google Scholar 

  36. Butler RC, Shah SM, Grunow WA, et al. Massive hepatic necrosis in a patient receiving allopurinol. JAMA. 1977;237:473–4.

    Article  PubMed  CAS  Google Scholar 

  37. Gelbart DR, Weinstein AB, Fajardo LF. Allopurinol-induced interstitial nephritis. Ann Intern Med. 1977;86:196–8.

    Article  PubMed  CAS  Google Scholar 

  38. Medline A, Cohen LB, Tobe BA, et al. Liver granulomas and allopurinol. Br Med J. 1978;1:1320–1.

    Article  PubMed  CAS  Google Scholar 

  39. Burkle WS. Allopurinol hypersensitivity. Drug Intell Clin Pharm. 1979;13:218–23.

    Google Scholar 

  40. Fam AG, Paton TW, Chaiton A. Reinstitution of allopurinol therapy for gouty arthritis after cutaneous reactions. Can Med Assoc J. 1980;123:128–9.

    PubMed  CAS  Google Scholar 

  41. Hamilton DV, Shah PJR, Pryor JS, et al. Acute vasculitis and exacerbation of renal failure secondary to allopurinol hypersensitivity. Dial Transpl. 1980;9:78.

    Google Scholar 

  42. Link F, Mueller-Fassbender H. Drug-induced lupus erythematodes (DILE): minor tranquillizers and allopurinol as general inducers of the DILE syndrome? [German] Medikamentos Induzierter Lupus Erythematodes. Minor-Tranquilizers Und Allopurinol Als ‘General Inducers’ Des Di-Le Syndroms. Munchener Medizinische Wochenschrift. 1980;122:1099–100.

    PubMed  CAS  Google Scholar 

  43. Daul AE, Graben N, Anlauf M, et al. Generalized vasculitis as potentially fatal side effect of allopurinol. [German] Generalisierte Vaskulitis Als Lebensbedrohliche Nebenwirkung Von Allopurinol. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin. 1981;87:1235–8.

    Google Scholar 

  44. Gotz VP, Salem R. Bullae associated with allopurinol. Drug Intell Clin Pharm. 1981;15:490–1.

    Google Scholar 

  45. Lee EJ, Kueh YK. Allopurinol-induced skin reactions and agranulocytosis. Singap Med J. 1982;23:178–80.

    CAS  Google Scholar 

  46. Ramond MJ, Nouel O, Degott C, et al. Allopurinol-induced hepatitis: report of a case and review of the literature (author’s transl). Gastroenterol Clin Biol. 1982;6:138–42.

    PubMed  CAS  Google Scholar 

  47. Bruguera M, Libre J, Aubia J, et al. Allopurinol-induced cholestasis. [Spanish] Colestasis Por Alopurinol. Gastroenterologia y Hepatologia. 1983;6:253–5.

    Google Scholar 

  48. Halebian P, Corder V, Herndon D, et al. A burn center experience with toxic epidermal necrolysis. J Burn Care Res. 1983;4:176–83.

    Article  Google Scholar 

  49. Dan M, Jedwab M, Peled M, et al. Allopurinol-induced toxic epidermal necrolysis. Int J Dermatol. 1984;23:142–4.

    Article  PubMed  CAS  Google Scholar 

  50. Fong PH, Ratnagopal P, Wong KL. Drug induced toxic epidermal necrolysis. Singap Med J. 1984;25:184–6.

    CAS  Google Scholar 

  51. Ebel V, Baumann R, Czechanowski B. Five cases of drug-induced Lyell’s syndrome. [German] Funf Falle Mit Medikamenten-Induziertem Lyell-Syndrom. Innere Medizin. 1985;12:280–4.

    Google Scholar 

  52. Renwick IG. Asymptomatic hyperuricemia and allopurinol induced toxic epidermal necrolysis. Br Med J. 1985;291:485 (Clinical Research Ed).

    Article  CAS  Google Scholar 

  53. Zakraoui L, Daly L, Hamza M. Lyell’s syndrome happened to a patient treated by allopurinol. [French] Syndrome De Lyell Survenant Chez Une Patiente Traitee Par L’allopurinol. Tunisie Medicale. 1985;63:167–70.

    PubMed  CAS  Google Scholar 

  54. Durst UN, Muller E, Pfister T. Toxic epidermal necrolysis (Lyell’s syndrome). [German] Toxische Epidermale Nekrolyse (Lyell-Syndrom). Schweiz Med Wochenschr. 1986;116:713–20.

    PubMed  CAS  Google Scholar 

  55. Johnston JB, Glazer RI, Pugh L, et al. The treatment of hairy-cell leukaemia with 2′-deoxycoformycin. Br J Haematol. 1986;63:525–34.

    Article  PubMed  CAS  Google Scholar 

  56. Kumar L. Allopurinol induced toxic epidermal necrolysis. Indian J Dermatol. 1986;31:53–4.

    PubMed  CAS  Google Scholar 

  57. Rayle RT. 5 nursing lessons from a patient with T.E.N. Am J Nurs. 1986;86:300–2.

    Article  PubMed  CAS  Google Scholar 

  58. Balacco-Gabrieli C, Palmisano C, Lorusso V, et al. Lyell’s syndrome caused by allopurinol. Clinical case. Ophtalmologie. 1988;2:123–6.

    PubMed  CAS  Google Scholar 

  59. Sauve C, Pinquier JL, Boissonnad A, et al. Systemic allopurinol toxicity. Eur J Intern Med. 1992;3:78–81.

    Google Scholar 

  60. Yu RC, Chu TC. Allopurinol-induced toxic pustuloderma. Br J Dermatol. 1993;128:95–8.

    Article  PubMed  CAS  Google Scholar 

  61. Carsuzaa F, Pierre C, Morand JJ, et al. Allopurinol hypersensitivity syndrome: Erythema annulare centrifugum. [French] Syndrome D’hypersensibilite a L’allopurinol a Type D’erytheme Annulaire Centrifuge. Nouvelles Dermatologiques. 1994;13:670–1.

    Google Scholar 

  62. Ioannides D, Vakali G, Chrysomallis F, et al. Toxic epidermal necrolysis: a study of 22 cases. J Eur Acad Dermatol Venereol. 1994;3:266–75.

    Article  Google Scholar 

  63. Richter G, Blasum C. Allopurinol hypersensitivity syndrome. [German] Allopurinol-Hypersensitivitatssyndrom. Aktuelle Dermatologie. 1994;20:217–9.

    Google Scholar 

  64. Bang HD, Chung JH, Cho KH, et al. Three cases of allopurinol hypersensitivity syndrome. Korean J Dermatol. 1995;33:130–4.

    Google Scholar 

  65. Baroni T, Bocor M. Erythemato-maculo-papular eruption induced by allopurinol. [Italian] Eruzione Eritemato-Maculo-Papulosa Da Allopurinolo. Giornale Italiano di Dermatologia e Venereologia. 1995;130:45–7.

    Google Scholar 

  66. Domingues-Costa A, Marques P, Vaz-Da-Silva M. The allopurinol hypersensitivity syndrome: A case report. [Portuguese] Sindrome De Hipersensibilidade Ao Alopurinol. A Proposito De Um Caso Clinico. Arquivos de Medicina. 1996;10:48–54.

    Google Scholar 

  67. Kruppa A, Smola H, Scharffetter-Kochanek K, et al. Allopurinol-induced allergic vasculitis. [German] Vasculitis allergica auf Allopurinol. H+G Zeitschrift fur Hautkrankheiten. 1996;71:868–9.

    Google Scholar 

  68. Gimbel Moral LF, De Miguel Sanchez C, Mugarza Hernandez MD, et al. Erupcion Fija Medicamentosa Causada Por Alopurinol. Medicina Clinica. 1996;106:119.

    Google Scholar 

  69. Sabaris Ma CF, Duran EP, Garcia-Patos PE, et al. Generalized acute exanthematic pustulosis due to allopurinol. [Spanish] Pustulosis exantematica aguda generalizada por alopurinol. Actas Dermo-Sifiliograficas. 1996;87:471–4.

    Google Scholar 

  70. Akriditis NK, Sakkas LI. Leukocytoclastic vasculitis. Consultant. 1997;37:1414.

    Google Scholar 

  71. Higuchi S, Yamamoto M. A case of Stevens–Johnson syndrome associated with allopurinol hypersensitivity [Japanese]. Acta Dermatologica Kyoto. 1997;92:367–73.

    Google Scholar 

  72. Schnyder B, Zanni MP, Pichler WJ. Drug-induced hypersensitivity syndrome. A review and presentation of 2 personal cases. Schweiz Med Wochenschr. 1997;127:355–9.

    PubMed  CAS  Google Scholar 

  73. Calvino JA, Burgos RR, Mardaras J, et al. Hypersensitivity syndrome and granulomatous interstitial nephritis associated with allopurinol. [Spanish] Sindrome de hipersensibilidad y nefritis intersticial granulomatosa aguda asociada al alopurinol. Nefrologia. 1998;18:238–42.

    Google Scholar 

  74. Choquet-Kastylevsky G, Intrator L, Chenal C, et al. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol. 1998;139:1026–32.

    Article  PubMed  CAS  Google Scholar 

  75. Kluger E. Fatal outcome in allopurinol hypersensitivity syndrome. Ugeskr Laeger. 1998;160:1179–80.

    PubMed  CAS  Google Scholar 

  76. Torralba FJ, Sanchez-Carbayo M, Gil MT, et al. Allopurinol hypersensitivity. [Spanish] Hipersensibilidad a alopurinol. Nefrologia. 1998;18:81–5.

    Google Scholar 

  77. Voets AJ, Joesoef KS. Allopurinol toxicity after coronary artery bypass grafting. Clin Intensive Care. 1998;9:88–9.

    Google Scholar 

  78. Wooten MD, Lipsmeyer E. Gout accompanying rheumatoid arthritis: a comparison of affected women and men. J Clin Rheumatol. 1998;4:220–4.

    PubMed  CAS  Google Scholar 

  79. Hari Y, Urwyler A, Hurni M, et al. Distinct serum cytokine levels in drug- and measles-induced exanthema. Int Arch Allergy Immunol. 1999;120:225–9.

    Article  PubMed  CAS  Google Scholar 

  80. Buna D. Allopurinol hypersensitivity syndrome: a case report and review. Can J Hosp Pharm. 2000;53:36–9.

    Google Scholar 

  81. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981–3.

    Article  PubMed  CAS  Google Scholar 

  82. Hari Y, Frutig-Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy. 2001;31:1398–408.

    Article  PubMed  CAS  Google Scholar 

  83. Ortega JD, Trindade C, Llamazares A, et al. Hypersensitivity to allopurinol. Efficacy of a desensitization procedure in three cases. [Spanish] Hipersensibilidad al alopurinol. Eficacia de un protocolo de desensibilizacion en tres casos. Anales de Medicina Interna. 2001;18:27–8.

    Google Scholar 

  84. Hoffman LA. My gout and allopurinol desensitization. J Clin Rheumatol. 2002;8:354–7.

    Article  PubMed  Google Scholar 

  85. Joshi A, Verma A, Gulati A, et al. Toxic epidermal necrolysis in a patient of chronic myeloid leukemia treated successfully with high dose steroids. J Inter Med India. 2002;5:40–2.

    Google Scholar 

  86. Maejima H, Mukai H, Hikaru E. Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide. Acta Derm Venereol. 2002;82:316–7.

    Article  PubMed  Google Scholar 

  87. Nishimura S, Shinoda T, Suzuki Y, et al. Drug-induced MPO-ANCA-positive necrotizing crescentic glomerulonephritis preceded by granulomatous hepatitis. Clin Exp Nephrol. 2002;6:118–20.

    Article  Google Scholar 

  88. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109:155–61.

    Article  PubMed  CAS  Google Scholar 

  89. Sommers LM, Schoene RB. Allopurinol hypersensitivity syndrome associated with pancreatic exocrine abnormalities and new-onset diabetes mellitus. Arch Intern Med. 2002;162:1190–2.

    Article  PubMed  Google Scholar 

  90. Chubar Y, Bennett M. Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol. Br J Haematol. 2003;122:768–70.

    Article  PubMed  CAS  Google Scholar 

  91. Hirashima N, Misago N, Nakafusa J, et al. Two cases of drug-induced hypersensitivity syndrome [Japanese]. Nishinihon J Dermatol. 2003;65:365–9.

    Article  Google Scholar 

  92. Kim BJ, Kim MN, Ro BI, et al. A case of allopurinol hypersensitivity syndrome [Korean]. Korean J Dermatol. 2003;41:251–4.

    Google Scholar 

  93. Nitti F, Fumagalli M, Incorvaia C. Rush desensitization to allopurynol. Allergy. 2003;58:690.

    Article  PubMed  CAS  Google Scholar 

  94. Koizumi H, Tsunoda T, Ito O, et al. A case of drug-induced hypersensitivity syndrome (DIHS) caused by allopurinol [Japanese]. Nishinihon J Dermatol. 2004;66:37–9.

    Article  Google Scholar 

  95. Takayasu S, Nasu N, Hoshino T, et al. Drug eruption associated with allopurinol and vancomycin in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD). A case report [Japanese]. Nishinihon J Dermatol. 2004;66:479–81.

    Article  Google Scholar 

  96. Cho WI, Yoon YH, Kim MN, et al. Two cases of allopurinol hypersensitivity syndrome due to use of allopurinol for the patient with asymptomatic hyperuricemia [Korean]. Korean J Dermatol. 2005;43:961–4.

    Google Scholar 

  97. Kim JW, Kim JS, Kim KJ. A clinical observation of drug hypersensitivity syndrome and serologic and molecular genetic analyses of human herpesvirus-6 reactivation [Korean]. Korean J Dermatol. 2005;43:143–50.

    Google Scholar 

  98. Kwon KS, Kim BS, Jang BS, et al. Clinical study of drug rash with eosinophilia and systemic symptoms (DRESS) on drug eruption patients over the last 10 years (1995–2004) [Korean]. Korean J Dermatol. 2005;43:1164–9.

    Google Scholar 

  99. Lin MS, Dai YS, Pwu RF, et al. Risk estimates for drugs suspected of being associated with Stevens–Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J. 2005;35:188–90.

    Article  PubMed  Google Scholar 

  100. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg. 2005;58:504–10.

    Article  PubMed  CAS  Google Scholar 

  101. Mantha S, Jacobs MI, Savage DG. Unusual leukemia presentations. Case 3. Type I IgGlambda cryoglobulinemia associated with chronic lymphocytic leukemia. J Clin Oncol. 2005;23:5841–3.

    Article  PubMed  Google Scholar 

  102. Marie E, Fournier C, Bautin N, et al. Ultra-rush desensitization to allopurinol. [French] Accoutumance ultrarapide a l’allopurinol. Revue Francaise d’Allergologie et d’Immunologie Clinique. 2005;45:498–500.

    Article  Google Scholar 

  103. Park MW, Kim SS, Lee JJ. Two cases of allopurinol hypersensitivity syndrome [Korean]. Korean J Dermatol. 2005;43:114–7.

    Google Scholar 

  104. Song HJ, Kim CO, Lee KS. Two cases of allopurinol hypersensitivity syndrome in patients receiving thiazide therapy due to hypertension [Korean]. Korean J Dermatol. 2005;43:1426–9.

    Google Scholar 

  105. Stingeni L, Zeppa L, Lisi P. Allopurinol induced DRESS syndrome: Clinical and pathogenetic remarks. [Italian] Sindrome da ipersensibilita ad allopurinolo: Considerazioni clinicopatogenetiche. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale. 2005;59:115–7.

    Google Scholar 

  106. Wang D, Xhu XJ. Gouty patient hypersensitive to allopurinol: an intractable case. J Dermatol. 2005;32:64–5.

    PubMed  Google Scholar 

  107. Das R. Allopurinol-associated angitis. J Pharm Pract Res. 2006;36:77.

    Google Scholar 

  108. Seishima M, Yamanaka S, Fujisawa T, et al. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol. 2006;155:344–9.

    Article  PubMed  CAS  Google Scholar 

  109. Torres MJ, Mayorga C, Fernandez TD, et al. T cell assessment in allergic drug reactions during the acute phase according to the time of occurrence. Int J Immunopathol Pharmacol. 2006;19:119–30.

    PubMed  CAS  Google Scholar 

  110. Vahid B, Wildemore B, Lin T, et al. What caused diffuse alveolar hemorrhage in a patient with gout? J Respir Dis. 2006;27:441–3.

    Article  CAS  Google Scholar 

  111. Wung DC, Cheng MF, Huang JJ, et al. Corticosteroid therapy in allopurinol hypersensitivity syndrome: a case report [Chinese]. J Intern Med Taiwan. 2006;17:133–40.

    Google Scholar 

  112. Calogiuri G, Muratore L, Congedo M, et al. Alternative treatments in allopurinol hypersensitivity syndrome: a case report. [Italian] Alternative terapeutiche nella sindrome da ipersensibilita all’allopurinolo: Descrizione di un caso clinico. Italian. J Allergy Clin Immunol. 2007;17:66–70.

    Google Scholar 

  113. Cornejo-Garcia JA, Fernandez TD, Torres MJ, et al. Differential cytokine and transcription factor expression in patients with allergic reactions to drugs. Allergy. 2007;62:1429–38.

    Article  PubMed  CAS  Google Scholar 

  114. Gravante G, Delogu D, Marianetti M, et al. Toxic epidermal necrolysis and Steven–Johnson syndrome: 11-years experience and outcome. Eur Rev Med Pharmacol Sci. 2007;11:119–27.

    PubMed  CAS  Google Scholar 

  115. Nishio D, Izu K, Kabashima K, et al. T cell populations propagating in the peripheral blood of patients with drug eruptions. J Dermatol Sci. 2007;48:25–33.

    Article  PubMed  CAS  Google Scholar 

  116. Paquet P, Jacob E, Quatresooz P, et al. Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis. Burns. 2007;33:100–4.

    Article  PubMed  CAS  Google Scholar 

  117. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int. 2007;56:419–25.

    Article  PubMed  CAS  Google Scholar 

  118. Fortunati M, Dewulf V, Jouret F, et al. “DRESS syndrome”or systemic allopurinol hypersensitivity syndrome. [French] «DRESS syndrome» ou syndrome d’hypersensibilite systemique a l’allopurinol. Louvain Med. 2008;127:376–9.

    Google Scholar 

  119. Roche Gamon E, Carazo JLS, Argente CL, et al. Delayed allopurinol hypersensitivity syndrome. [Spanish] Sindrome de hipersensibilidad retardada a alopurinol. Piel. 2008;23:166–8.

    Article  Google Scholar 

  120. Koike M, Kanno Y, Tomori K, et al. Viruses may trigger allopurinol hypersensitivity syndrome. NDT Plus. 2008;1:273–4.

    Article  Google Scholar 

  121. Tausche AK, Aringer M, Schroeder HE, et al. The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med. 2008;121:e3–4.

    Article  PubMed  Google Scholar 

  122. Tohyama M, Shirakata Y, Sayama K, et al. A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome. Br J Dermatol. 2008;159:981–4.

    Article  PubMed  CAS  Google Scholar 

  123. Asano Y, Kagawa H, Kano Y, et al. Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch Dermatol. 2009;145:1030–6.

    Article  PubMed  Google Scholar 

  124. Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum. 2009;61:1268–70.

    Article  PubMed  Google Scholar 

  125. Kemen C, Lemke J, Hoeger PH, et al. Human leukocyte antigen-related risk factors for toxic epidermal necrosis. Pediatr Infect Dis J. 2009;28:552.

    Article  PubMed  Google Scholar 

  126. Tamzaourte M, Errabih I, Krami H, et al. Acute cytolytic hepatitis induced by allopurinol in a patient treated for hepatitis C. [French] Hepatite aigue cytolytique induite par l’allopurinol chez un patient traite pour hepatite virale C. Journal Africain d’Hepato-Gastroenterologie. 2009;3:160–2.

    Article  Google Scholar 

  127. Ang CC, Wang YS, Yoosuff EL, et al. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol. 2010;63:219–27.

    Article  PubMed  Google Scholar 

  128. Bellon T, Alvarez L, Mayorga C, et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. Br J Dermatol. 2010;162:1014–22.

    Article  PubMed  CAS  Google Scholar 

  129. Bennett S, Mitsides N, Dhaygude A, et al. A pilot in distress. NDT Plus. 2010;3:84–8.

    Article  Google Scholar 

  130. Chaabane A, Aouam K, Fredj NB, et al. DRESS syndrome: 11 Case reports and a literature review. [French] DRESS syndrome: Etude de 11 cas et revue de la litterature. Therapie. 2010;65:543–50.

    Article  PubMed  Google Scholar 

  131. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146:1373–9.

    Article  PubMed  Google Scholar 

  132. Cooksley T, Iqbal J, Robertson C, et al. DRESS syndrome caused by allopurinol. Acute Med. 2010;9:122–3.

    PubMed  Google Scholar 

  133. Elia F, Apra F. A potentially fatal cause of rash. Int J Emerg Med. 2010;3:491–2.

    Article  PubMed  Google Scholar 

  134. Flores SM, Hidalgo LG, Topete RO. Erithrodermia as presentation of DRESS syndrome associated with allopurinol. A report of a case. [Spanish] Eritrodermia como presentacion del sindrome DRESS asociado con alopurinol. Comunicacion de un caso. Dermatologia Revista Mexicana. 2010;54:104–7.

    Google Scholar 

  135. Ben Fredj N, Aouam K, Chaabane A, et al. Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization. Br J Clin Pharmacol. 2010;70:273–6.

    Article  PubMed  CAS  Google Scholar 

  136. Lee T, Bae YJ, Park SK, et al. Severe pneumonia caused by combined infection with Pneumocystis jiroveci, parainfluenza virus type 3, cytomegalovirus, and Aspergillus fumigatus in a patient with Stevens–Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2010;90:625–9.

    Article  PubMed  Google Scholar 

  137. Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E, et al. Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on human herpesvirus 6 replication in vitro. Eur J Dermatol. 2010;20:68–73.

    PubMed  CAS  Google Scholar 

  138. Peppercorn AF, Miller MB, Fitzgerald D, et al. High-level human herpesvirus-6 viremia associated with onset of Stevens–Johnson syndrome: report of two cases. J Burn Care Res. 2010;31:365–8.

    Article  PubMed  Google Scholar 

  139. Cardoso CS, Vieira AM, Oliveira AP. DRESS syndrome: a case report and literature review. BMJ Case Rep. 2011. doi:10.1136/bcr.02.2011.3898.

  140. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38:1957–9.

    Article  PubMed  CAS  Google Scholar 

  141. Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transpl. 2011;26:3567–72.

    Article  CAS  Google Scholar 

  142. Natkunarajah J, Goolamali S, Craythorne E, et al. Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol. 2011;21:385–91.

    PubMed  Google Scholar 

  143. Ranu H, Jiang J, Ming PS. A case series of allopurinol-induced toxic epidermal necrolysis. Indian J Dermatol. 2011;56:74–6.

    Article  PubMed  Google Scholar 

  144. Teo WL, Pang SM, Koh HY. Allopurinol hypersensitivity syndrome with acute generalized exanthematous pustulosis manifestations. Cutan Ocul Toxicol. 2011;30:243–4.

    Article  PubMed  Google Scholar 

  145. Aach R, Kissane J. Hypertension, hyperuricemia and iatrogenic disease. Am J Med. 1970;49:242–9.

    Article  Google Scholar 

  146. Jarzobski J, Ferry J, Wombolt D, et al. Vasculitis with allopurinol therapy. Am Heart J. 1970;79:116–21.

    Article  PubMed  CAS  Google Scholar 

  147. Mills RM Jr. Severe hypersensitivity reactions associated with allopurinol. JAMA. 1971;216:799–802.

    Article  PubMed  Google Scholar 

  148. Simmons F, Feldman B, Gerety D. Granulomatous hepatitis in a patient receiving allopurinol. Gastroenterology. 1972;62:101–4.

    PubMed  CAS  Google Scholar 

  149. Young JL Jr, Boswell RB, Nies AS. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med. 1974;134:553–8.

    Article  PubMed  Google Scholar 

  150. Ellman MH, Fretzin DF, Olson W. Toxic epidermal necrolysis associated with allopurinol administration. Arch Dermatol. 1975;111:986–90.

    Article  PubMed  CAS  Google Scholar 

  151. Boyer TD, Sun N, Reynolds TB. Allopurinol-hypersensitivity vasculitis and liver damage. West J Med. 1977;126:143–7.

    PubMed  CAS  Google Scholar 

  152. Lockard O Jr, Harmon C, Nolph K, et al. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann Intern Med. 1976;85:333–5.

    Article  PubMed  Google Scholar 

  153. McMenamin RA, Davies LM, Craswell PW. Drug induced interstitial nephritis, hepatitis and exfoliative dermatitis. Aust N Z J Med. 1976;6:583–7.

    Article  PubMed  CAS  Google Scholar 

  154. Utsinger PD, Young WJ. Allopurinol hypersensitivity. Granular deposition of IgM at the dermal-epidermal junction. Am J Med. 1976;61:287–94.

    Article  PubMed  CAS  Google Scholar 

  155. Chan HL, Ku G, Khoo OT. Allopurinol associated hypersensitivity reactions: cutaneous and renal manifestations. Aust N Z J Med. 1977;7:518–22.

    Article  PubMed  CAS  Google Scholar 

  156. Devulder B, Plouvier B, Francois M, et al. Zeek’s angiitis during combination treatment with allopurinol and a thiazide diuretic. Lille Med. 1977;22:798–800.

    PubMed  CAS  Google Scholar 

  157. Calin A. Allopurinol toxicity masquerading as malignancy. JAMA. 1978;239:497.

    Article  PubMed  CAS  Google Scholar 

  158. Korting HC, Lesch R. Acute cholangitis after allopurinol treatment. Lancet. 1978;1:275–6.

    Article  PubMed  CAS  Google Scholar 

  159. Lindsey SW, Evans EF. Allpurinol hypersensitivity syndrome: effects and treatment. Va Med. 1978;105:297–9.

    PubMed  CAS  Google Scholar 

  160. Male PJ, Schaer B, Posternak F. Hypersensitivity reaction to allopurinol. Schweiz Med Wochenschr. 1978;108:681–3.

    PubMed  CAS  Google Scholar 

  161. Swank LA, Chejfec G, Nemchausky BA. Allopurinol-induced granulomatous hepatitis with cholangitis and a sarcoid-like reaction. Arch Intern Med. 1978;138:997–8.

    Article  PubMed  CAS  Google Scholar 

  162. Haughey DB, Lanse S, Imhoff T, et al. Allopurinol sensitivity: report of two cases. Am J Hosp Pharm. 1979;36:1377–80.

    PubMed  CAS  Google Scholar 

  163. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol. 1979;1:365–74.

    Article  PubMed  CAS  Google Scholar 

  164. McKendrick MW, Geddes AM. Allopurinol hypersensitivity. Br Med J. 1979;1:988.

    Article  PubMed  CAS  Google Scholar 

  165. Phanichphant S, Boonpucknavig V. Allopurinol associated hypersensitivity. J Med Assoc Thai. 1980;63:155–63.

    PubMed  CAS  Google Scholar 

  166. Al-Kawas FH, Seeff LB, Berendson RA, et al. Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med. 1981;95:588–90.

    Article  PubMed  CAS  Google Scholar 

  167. Grussendorf M, Andrassy K, Waldherr R, et al. Systemic hypersensitivity to allopurinol with acute interstitial nephritis. Am J Nephrol. 1981;1:105–9.

    Article  PubMed  CAS  Google Scholar 

  168. Irino S, Sanada H, Maesako N, et al. A case of angio-immunoblastic lymphadenopathy with dysproteinemia related to allopurinol. Acta Med Okayama. 1981;35:263–72.

    PubMed  CAS  Google Scholar 

  169. Earll JM, Saavedra M. Oxipurinol therapy in allopurinol-allergic patients. Am Fam Physician. 1983;28:147–8.

    PubMed  CAS  Google Scholar 

  170. Ohsawa T, Ohtsubo M. Hepatitis associated with allopurinol. Drug Intell Clin Pharm. 1985;19:431–3.

    PubMed  CAS  Google Scholar 

  171. Stein CM. Allopurinol hypersensitivity. A case report. S Afr Med J. 1985;67:935–6.

    PubMed  CAS  Google Scholar 

  172. Webster E, Panush RS. Allopurinol hypersensitivity in a patient with severe, chronic, tophaceous gout. Arthritis Rheum. 1985;28:707–9.

    Article  PubMed  CAS  Google Scholar 

  173. Guerin C, Genin C, Toulon J, et al. Allopurinol toxicity. Apropos of 1 case. Nephrologie. 1986;7:47–9.

    PubMed  CAS  Google Scholar 

  174. Handa SP. Drug-induced acute interstitial nephritis: report of 10 cases. CMAJ. 1986;135:1278–81.

    PubMed  CAS  Google Scholar 

  175. Magner P, Sweet J, Bear RA. Granulomatous interstitial nephritis associated with allopurinol therapy. CMAJ. 1986;135:496–7.

    PubMed  CAS  Google Scholar 

  176. Mousson C, Justrabo E, Tanter Y, et al. Acute granulomatous interstitial nephritis and hepatitis caused by drugs. Possible role of an allopurinol-furosemide combination. Nephrologie. 1986;7:199–203.

    PubMed  CAS  Google Scholar 

  177. Pan HY, Glazener FS. The mackerel was in fact a red herring. Drug Intell Clin Pharm. 1986;20:687–9.

    PubMed  CAS  Google Scholar 

  178. Schillinger F, Montagnac R, Milcent T. A new case of severe allopurinol toxicity. Nephrologie. 1986;7:214.

    PubMed  CAS  Google Scholar 

  179. Vanderstigel M, Zafrani ES, Lejonc JL, et al. Allopurinol hypersensitivity syndrome as a cause of hepatic fibrin-ring granulomas. Gastroenterology. 1986;90:188–90.

    PubMed  CAS  Google Scholar 

  180. Arbeteta J, Ledo L, Teruel JL, et al. Severe adverse reaction to allopurinol. Med Clin (Barc). 1987;88:125–6.

    CAS  Google Scholar 

  181. Pewsner D, Bachmann C, Muller U. Allopurinol-induced kidney failure with hepatitis and squamous dermatitis in pre-existing kidney insufficiency. Schweiz Med Wochenschr. 1987;117:139–41.

    PubMed  CAS  Google Scholar 

  182. Emmerson BT, Hazelton RA, Frazer IH. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum. 1988;31:436–40.

    Article  PubMed  CAS  Google Scholar 

  183. Foucault V, Pibouin M, Lehry D, et al. Severe drug accidents and allopurinol. Ann Dermatol Venereol. 1988;115:1169–72.

    PubMed  CAS  Google Scholar 

  184. McDonald J, Fam AG, Paton T, et al. Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout. J Rheumatol. 1988;15:865–8.

    PubMed  CAS  Google Scholar 

  185. Casas E, Puig JG, Mateos FA, et al. The allopurinol hypersensitivity syndrome: its relation to plasma oxypurinol levels. Adv Exp Med Biol. 1989;253A:257–60.

    Article  PubMed  CAS  Google Scholar 

  186. Coutellier P, Delgrange B. Fatal toxic epidermolysis following administration of allopurinol. Acta Clin Belg. 1989;44:196–8.

    PubMed  CAS  Google Scholar 

  187. Gram JT, Gundersen T. Allopurinol hypersensitivity syndrome. Tidsskr Nor Laegeforen. 1989;109:3102–4.

    PubMed  CAS  Google Scholar 

  188. Puig JG, Casas EA, Ramos TH, et al. Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity. J Rheumatol. 1989;16:842–4.

    PubMed  CAS  Google Scholar 

  189. Stricker BH, Blok AP, Babany G, et al. Fibrin ring granulomas and allopurinol. Gastroenterology. 1989;96:1199–203.

    PubMed  CAS  Google Scholar 

  190. Chong RS, Ng HS, Teh LB, et al. Hepatic granulomas: an experience over the last 8 years. Singap Med J. 1990;31:422–6.

    CAS  Google Scholar 

  191. Collins CE, Thomas DJ, Gumpel JM. Catatonia in the allopurinol hypersensitivity syndrome. BMJ. 1991;302:970.

    Article  PubMed  CAS  Google Scholar 

  192. Marazuela M, Moreno A, Yebra M, et al. Hepatic fibrin-ring granulomas: a clinicopathologic study of 23 patients. Hum Pathol. 1991;22:607–13.

    Article  PubMed  CAS  Google Scholar 

  193. Walz-LeBlanc BA, Reynolds WJ, MacFadden DK. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum. 1991;34:1329–31.

    Article  PubMed  CAS  Google Scholar 

  194. Fam AG, Lewtas J, Stein J, et al. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med. 1992;93:299–302.

    Article  PubMed  CAS  Google Scholar 

  195. San Andres Rebollo FJ, Gonzalez Rubio M, Postigo C, et al. Hypersensitivity syndrome caused by allopurinol: report of 2 cases and review of the literature. Rev Clin Esp. 1992;191:426–9.

    PubMed  CAS  Google Scholar 

  196. Huang RY, Liu HN, Wong CK. Stevens–Johnson syndrome: a review of 42 cases. Zhonghua Yi Xue Za Zhi (Taipei). 1993;51:225–30.

    CAS  Google Scholar 

  197. Berbegal J, Morera J, Andrada E, et al. Syndrome of allopurinol hypersensitivity. Report of a new case and review of the Spanish literature. Med Clin (Barc). 1994;102:178–80.

    CAS  Google Scholar 

  198. Braden GL, Warzynski MJ, Golightly M, et al. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol. 1994;70:145–51.

    Article  PubMed  CAS  Google Scholar 

  199. Fitzgerald DA, Heagerty AH, Stephens M, et al. Follicular toxic pustuloderma associated with allopurinol. Clin Exp Dermatol. 1994;19:243–5.

    Article  PubMed  CAS  Google Scholar 

  200. Hanger HC, Pillans PI. Death following allopurinol hypersensitivity syndrome. N Z Med J. 1994;107:229.

    PubMed  CAS  Google Scholar 

  201. Lee SS, Lin HY, Wang SR, et al. Allopurinol hypersensitivity syndrome. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1994;27:140–7.

    PubMed  CAS  Google Scholar 

  202. Salinas Martin A, Mendez Abad M, Miguelez M, et al. Hypersensitivity reaction to allopurinol. Aten Primaria. 1994;14:694.

    PubMed  CAS  Google Scholar 

  203. Elasy T, Kaminsky D, Tracy M, et al. Allopurinol hypersensitivity syndrome revisited. West J Med. 1995;162:360–1.

    PubMed  CAS  Google Scholar 

  204. Gonzalez U, Reyes E, Kershenovich J, et al. Hypersensitivity syndrome caused by allopurinol. A case of massive hepatic necrosis. Rev Invest Clin. 1995;47:409–13.

    PubMed  CAS  Google Scholar 

  205. Parra E, Gota R, Gamen A, et al. Granulomatous interstitial nephritis secondary to allopurinol treatment. Clin Nephrol. 1995;43:350.

    PubMed  CAS  Google Scholar 

  206. Urban T, Maquarre E, Housset C, et al. Allopurinol hypersensitivity: a possible cause of hepatitis and mucocutaneous eruptions in a patient undergoing antitubercular treatment. Rev Mal Respir. 1995;12:314–6.

    PubMed  CAS  Google Scholar 

  207. Kumar A, Edward N, White MI, et al. Allopurinol, erythema multiforme, and renal insufficiency. BMJ. 1996;312:173–4.

    Article  PubMed  CAS  Google Scholar 

  208. Rothwell PM, Grant R. Cerebral vasculitis following allopurinol treatment. Postgrad Med J. 1996;72:119–20.

    Article  PubMed  CAS  Google Scholar 

  209. Andrade RJ, de la Mata M, Lucena MI, et al. Severe acute hepatitis due to allopurinol in a patient with asymptomatic hyperuricemia and kidney failure. A review of the literature and an analysis of the risk factors. Gastroenterol Hepatol. 1997;20:353–6.

    PubMed  CAS  Google Scholar 

  210. Carpenter C. Allopurinol hypersensitivity syndrome. Tenn Med. 1997;90:151–2.

    PubMed  CAS  Google Scholar 

  211. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23:1237–44.

    Article  PubMed  CAS  Google Scholar 

  212. Choi HK, Merkel PA, Niles JL. ANCA-positive vasculitis associated with allopurinol therapy. Clin Exp Rheumatol. 1998;16:743–4.

    PubMed  CAS  Google Scholar 

  213. Gillott TJ, Whallett A, Zaphiropoulos G. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity. Rheumatology (Oxford). 1999;38:85–6.

    Article  CAS  Google Scholar 

  214. Grahame R, Simmonds HA, McBride MB, et al. How should we treat tophaceous gout in patients with allopurinol hypersensitivity? Adv Exp Med Biol. 1998;431:19–23.

    Article  PubMed  CAS  Google Scholar 

  215. Hamanaka H, Mizutani H, Nouchi N, et al. Allopurinol hypersensitivity syndrome: hypersensitivity to oxypurinol but not allopurinol. Clin Exp Dermatol. 1998;23:32–4.

    Article  PubMed  CAS  Google Scholar 

  216. Jappe U, Franke I, Wendekamm U, et al. Allopurinol as an inducer of acute graft-versus-host-like drug reaction. Case report with review of the literature. Hautarzt. 1998;49:126–30.

    Article  PubMed  CAS  Google Scholar 

  217. Pereira S, Almeida J, Silva AO, et al. Fatal liver necrosis due to allopurinol. Acta Med Port. 1998;11:1141–4.

    PubMed  CAS  Google Scholar 

  218. Pluim HJ, van Deuren M, Wetzels JF. The allopurinol hypersensitivity syndrome. Neth J Med. 1998;52:107–10.

    Article  PubMed  CAS  Google Scholar 

  219. Suzuki Y, Inagi R, Aono T, et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol. 1998;134:1108–12.

    Article  PubMed  CAS  Google Scholar 

  220. Woss E, Neyer U. Hypersensitivity angiitis following allopurinol therapy. Fortschr Med. 1988;106(730–1):29.

    Google Scholar 

  221. Morel D, Guez S, Merville P, et al. Recurrent renal failure associated with hypersensitivity to allopurinol. Nephrol Dial Transpl. 1999;14:780–1.

    Article  CAS  Google Scholar 

  222. Tanna SB, Barnes JF, Seth SK. Desensitization to allopurinol in a patient with previous failed desensitization. Ann Pharmacother. 1999;33:1180–3.

    Article  PubMed  CAS  Google Scholar 

  223. Aoki S, Kotooka N, Yokoyama M, et al. Recurrence of rapidly progressive glomerulonephritis probably associated with two different kinds of drugs. Clin Nephrol. 2000;54:249–51.

    PubMed  CAS  Google Scholar 

  224. Brand R, Rohr JB. Toxic epidermal necrolysis in Western Australia. Australas J Dermatol. 2000;41:31–3.

    Article  PubMed  CAS  Google Scholar 

  225. Khoo BP, Leow YH. A review of inpatients with adverse drug reactions to allopurinol. Singap Med J. 2000;41:156–60.

    CAS  Google Scholar 

  226. Arakawa M, Kakuto Y, Ichikawa K, et al. Allopurinol hypersensitivity syndrome associated with systemic cytomegalovirus infection and systemic bacteremia. Intern Med. 2001;40:331–5.

    Article  PubMed  CAS  Google Scholar 

  227. Benito-Leon J, Porta-Etessam J. Guillain–Barre syndrome and allopurinol-induced hypersensitivity. Eur Neurol. 2001;45:186–7.

    Article  PubMed  CAS  Google Scholar 

  228. Hammer B, Link A, Wagner A, et al. Hypersensitivity syndrome during therapy with allopurinol in asymptomatic hyperuricemia with a fatal outcome. Dtsch Med Wochenschr. 2001;126:1331–4.

    Article  PubMed  CAS  Google Scholar 

  229. Rivas Gonzalez P, Calvo Hernandez R, Molinelli Barranco M, et al. Allopurinol hypersensitivity syndrome. Rev Clin Esp. 2001;201:493.

    Article  PubMed  CAS  Google Scholar 

  230. Anderson BE, Adams DR. Allopurinol hypersensitivity syndrome. J Drugs Dermatol. 2002;1:60–2.

    PubMed  Google Scholar 

  231. Descamps V, Mahe E, Houhou N, et al. Drug-induced hypersensitivity syndrome associated with Epstein–Barr virus infection. Br J Dermatol. 2003;148:1032–4.

    Article  PubMed  CAS  Google Scholar 

  232. Fine P, Savrinski B, Millodot M. Contact lens management of a case of Stevens–Johnson syndrome: a case report. Optometry. 2003;74:659–64.

    PubMed  Google Scholar 

  233. Masaki T, Fukunaga A, Tohyama M, et al. Human herpes virus 6 encephalitis in allopurinol-induced hypersensitivity syndrome. Acta Derm Venereol. 2003;83:128–31.

    Article  PubMed  CAS  Google Scholar 

  234. Mete N, Yilmaz F, Gulbahar O, et al. Allopurinol hypersensitivity syndrome as a cause of hepatic centrilobular hemorrhagic necrosis. J Investig Allergol Clin Immunol. 2003;13:281–3.

    PubMed  CAS  Google Scholar 

  235. Dia D, Ba-Fall K, Bouldouyre M, et al. DRESS syndrome to allopurinol: a case in Dakar. Dakar Med. 2004;49:114–5.

    PubMed  CAS  Google Scholar 

  236. Marrakchi C, Kanoun F, Kilani B, et al. Allopurinol induced DRESS syndrome. Rev Med Interne. 2004;25:252–4.

    Article  PubMed  CAS  Google Scholar 

  237. Chao SC, Yang CC, Lee JY. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease. Ann Pharmacother. 2005;39:1552–6.

    Article  PubMed  Google Scholar 

  238. Chen IH, Kuo MC, Hwang SJ, et al. Allopurinol-induced severe hypersensitivity with acute renal failure. Kaohsiung J Med Sci. 2005;21:228–32.

    Article  PubMed  Google Scholar 

  239. Choi SH, Yang SH, Song YB, et al. A case of vanishing bile duct syndrome associated with hypersensitivity to allopurinol. Korean J Hepatol. 2005;11:80–5.

    PubMed  Google Scholar 

  240. Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, et al. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ. 2005;331:623–4.

    Article  PubMed  Google Scholar 

  241. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134–9.

    Article  PubMed  CAS  Google Scholar 

  242. Kakeda M, Tohyama M, Iwasaki J, et al. A case of histopathologically typical toxic epidermal necrolysis despite no visible blisters or erosive lesions. J Dermatol. 2005;32:654–60.

    PubMed  Google Scholar 

  243. Saxena R, Loghmanee F. Fatal drug reaction due to allopurinol therapy in a 72-year-old man. Arch Pathol Lab Med. 2005;129:e183–4.

    PubMed  Google Scholar 

  244. Almirall J, Orellana R, Martinez Ocana JC, et al. Allopurinol-induced chronic granulomatous interstitial nephritis. Nefrologia. 2006;26:741–4.

    PubMed  CAS  Google Scholar 

  245. Kokunai A, Azusawa H, Murota H, et al. Hypersensitivity reactions to multiple drugs during the course of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Arerugi. 2006;55:662–6.

    PubMed  Google Scholar 

  246. Rodevand E, Sletvold O, Kvande KT. Side effects off allopurinol. Tidsskr Nor Laegeforen. 2004;124:2618–9.

    PubMed  Google Scholar 

  247. Dainichi T, Uchi H, Moroi Y, et al. Stevens–Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology. 2007;215:86–8.

    Article  PubMed  Google Scholar 

  248. Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007;157:934–40.

    Article  PubMed  CAS  Google Scholar 

  249. Chiou CC, Yang LC, Hung SI, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 2008;22:1044–9.

    Article  PubMed  Google Scholar 

  250. Fagugli RM, Gentile G, Ferrara G, et al. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol. 2008;70:523–6.

    Article  PubMed  CAS  Google Scholar 

  251. Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singap Med J. 2008;49:384–7.

    CAS  Google Scholar 

  252. Shalom R, Rimbroth S, Rozenman D, et al. Allopurinol-induced recurrent DRESS syndrome: pathophysiology and treatment. Ren Fail. 2008;30:327–9.

    Article  PubMed  CAS  Google Scholar 

  253. Suzuki HI, Asai T, Tamaki Z, et al. Drug-induced hypersensitivity syndrome with rapid hematopoietic reconstitution during treatment for acute myeloid leukemia. Haematologica. 2008;93:469–70.

    Article  PubMed  Google Scholar 

  254. Yoon JY, Min SY, Park JY, et al. A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis. Korean J Hepatol. 2008;14:97–101.

    Article  PubMed  Google Scholar 

  255. Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009;145:67–72.

    Article  PubMed  Google Scholar 

  256. Gyotoku E, Iwamoto T, Ochi M. A fatal case of drug-induced hypersensitivity syndrome due to allopurinol. Arerugi. 2009;58:560–6.

    PubMed  Google Scholar 

  257. Hung CC, Liu WC, Kuo MC, et al. Acute renal failure and its risk factors in Stevens–Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol. 2009;29:633–8.

    Article  PubMed  CAS  Google Scholar 

  258. Hsieh HJ, Chan AL, Lin SJ. Stevens–Johnson syndrome induced by combination of imatinib and allopurinol. Chemotherapy. 2009;55:197–9.

    Article  PubMed  CAS  Google Scholar 

  259. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51–6.

    Article  PubMed  CAS  Google Scholar 

  260. Sackesen C, Dut R, Gucer S, et al. Allopurinol-induced DRESS syndrome in a 13-year-old girl. J Investig Allergol Clin Immunol. 2009;19:65–7.

    PubMed  CAS  Google Scholar 

  261. Dewan AK, Quinonez RA. Allopurinol-induced DRESS syndrome in an adolescent patient. Pediatr Dermatol. 2010;27:270–3.

    Article  PubMed  Google Scholar 

  262. Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2010;49:834–41.

    PubMed  Google Scholar 

  263. Fathallah N, Ben Salem C, Slim R, et al. Fatal allopurinol-induced hypersensitivity syndrome associated with pancreatic abnormalities. J Clin Rheumatol. 2010;16:170–1.

    Article  PubMed  Google Scholar 

  264. Hamaguchi Y, Fujimoto M, Enokido Y, et al. Intractable genital ulcers from herpes simplex virus reactivation in drug-induced hypersensitivity syndrome caused by allopurinol. Int J Dermatol. 2010;49:700–4.

    Article  PubMed  Google Scholar 

  265. Santiago F, Goncalo M, Vieira R, et al. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermat. 2010;62:47–53.

    Article  CAS  Google Scholar 

  266. Ventura F, Fracasso T, Leoncini A, et al. Death caused by toxic epidermal necrolysis (Lyell syndrome). J Forensic Sci. 2010;55:839–41.

    Article  PubMed  Google Scholar 

  267. Yang DC, Chang CM. Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome with recurrence. J Am Geriatr Soc. 2010;58:2043–4.

    Article  PubMed  Google Scholar 

  268. Taylor TH, Mecchella JN, Larson RJ, et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 2012;125:1126 e7–34 e7.

    Article  CAS  Google Scholar 

  269. Sekine A, Saito T, Ito S, et al. Two cases of tuberculosis with multiple drug hypersensitivity after drug-induced hypersensitivity syndrome. Respir Investig. 2012;50:70–5.

    Article  PubMed  Google Scholar 

  270. Agnes K, Anna L, Anita V, et al. Allopurinol-induced hypersensitivity syndrome. Orvosi Hetilap. 2012;153:586–91.

    Article  Google Scholar 

  271. Cao ZH, Wei ZY, Zhu QY, et al. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics. 2012;13:1193–201.

    Article  PubMed  CAS  Google Scholar 

  272. Comparin C, Hans Filho G, Takita LC, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin: a series of three cases. An Bras Dermatol. 2012;87:477–81.

    Article  PubMed  Google Scholar 

  273. Kamal T, Elnikety S, Mashaly H, et al. Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report. J Med Case Rep. 2012;6:84.

    Article  PubMed  Google Scholar 

  274. Biagioni E, Busani S, Rinaldi L, et al. Acute renal failure and liver necrosis associated to allopurinol therapy. Anaesth Intensive Care. 2012;40:190–1.

    PubMed  Google Scholar 

  275. Botelho LF, Higashi VS, Padilha MH, et al. DRESS: clinicopathological features of 10 cases from an University Hospital in Sao Paulo. An Bras Dermatol. 2012;87:703–7.

    Article  PubMed  Google Scholar 

  276. Chiu ML, Hu M, Ng MH, et al. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol. 2012;167:44–9.

    Article  PubMed  CAS  Google Scholar 

  277. Gordon K, Miteva M, Torchia D, et al. Allopurinol-induced palisaded neutrophilic and granulomatous dermatitis. Cutan Ocul Toxicol. 2012;31:338–40.

    Article  PubMed  Google Scholar 

  278. Huang YC, Shih PY, Chin SY, et al. Allopurinol-induced drug rash with eosinophilia and systemic symptoms mimicking acute generalized exanthematous pustulosis. J Dermatol. 2012;39:1077–8.

    Article  PubMed  Google Scholar 

  279. Lee MH, Stocker SL, Anderson J, et al. Initiating allopurinol therapy: do we need to know the patient’s human leucocyte antigen status? Intern Med J. 2012;42:411–6.

    Article  PubMed  CAS  Google Scholar 

  280. Martinez-Aranguren R, Gamboa PM, Garcia-Lirio E, et al. In vitro cytokine production after in vivo desensitization in an allopurinol-induced delayed allergic reaction. Ann Allergy Asthma Immunol. 2012;108:280–1.

    Article  PubMed  CAS  Google Scholar 

  281. Yaylaci S, Demir MV, Temiz T, et al. Allopurinol-induced DRESS syndrome. Indian J Pharmacol. 2012;44:412–4.

    Article  PubMed  CAS  Google Scholar 

  282. Wongkitisophon P, Chanprapaph K, Rattanakaemakorn P, et al. Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms. Acta Derm Venereol. 2012;92:200–5.

    Article  PubMed  CAS  Google Scholar 

  283. Onuma H, Tohyama M, Imagawa A, et al. High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome. J Clin Endocrinol Metab. 2012;97:E2277–81.

    Article  PubMed  CAS  Google Scholar 

  284. Laguna C, Martin B, Torrijos A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis. Actas Dermo-Sifiliograficas. 2006;97:177–85.

    Article  PubMed  Google Scholar 

  285. Raymond JZ, Goldman HM. An unusual cutaneous reaction secondary to allopurinol. Cutis. 1988;41:323–6.

    PubMed  CAS  Google Scholar 

  286. Fonseka MM, Sathischandra H, Jayamanne SF, et al. Successful desensitisation of allopurinol-induced erythema multiforme. Ceylon Med J. 1999;44:190–1.

    PubMed  CAS  Google Scholar 

  287. Edwards R, Ridder M. Stevens–Johnson syndrome: a multisystem case. Dimens Crit Care Nurs. 1985;4:335–48.

    Article  PubMed  CAS  Google Scholar 

  288. Teo L, Tay YK, Liu TT, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options. Singap Med J. 2009;50:29–33.

    CAS  Google Scholar 

  289. Turki H, Walha N, Boudaya S, et al. Le syndrome de Lyell (nécrolyse épidermique toxique). Étude de 8 cas. Sem Hôp Paris. 1998;74:953–8.

    Google Scholar 

  290. Gil Gonzalez I, Gimenez Garcia RM, Diez Gonzalez G, et al. Toxic epidermal necrolysis caused by allopurinol. Anales de Medicina Interna. 1988;5:649.

    Google Scholar 

  291. Quintas S, Do Carmo G, Gama R, et al. Lyell’s syndrome in a patient with AIDS. Acta Medica Portuguesa. 1997;10:509–16.

    PubMed  CAS  Google Scholar 

  292. Cid Conde L, Novoa Fernandez E, Padron Rodriguez B. Toxic epidermal necrolysis (Lyell’s syndrome) secondary to alopurinol. Farmacia Hospitalaria. 2009;33:229–30.

    Article  PubMed  CAS  Google Scholar 

  293. Knezevic A, Frkovic A, Francetic I, et al. Toxic epidermal necrolysis (Lyell’s syndrome) caused by allopurinol. Lijecnicki Vjesnik. 1987;109:272–4.

    PubMed  CAS  Google Scholar 

  294. Dicle Ö, Yilmaz E, Alpsoy E. Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective evaluation. Türkderm Deri Hastaliklari ve Frengi Arsivi. 2009;43:15–20.

    Google Scholar 

  295. Assaad D, From L, Ricciatti D, et al. Toxic epidermal necrolysis in Stevens–Johnson syndrome. Can Med Assoc J. 1978;118:154–6.

    PubMed  CAS  Google Scholar 

  296. Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol. 1994;130:605–8.

    Article  PubMed  CAS  Google Scholar 

  297. Gambert SR. Medication-induced Stevens–Johnson syndrome in elders. Clin Geriatr. 2012;20:8.

    Google Scholar 

  298. Stenton SB, Dalen D, Wilbur K. Myocardial infarction associated with intravenous immune globulin. Ann Pharmacother. 2005;39:2114–8.

    Article  PubMed  Google Scholar 

  299. Bennett TO, Sugar J, Sahgal S. Ocular manifestations of toxic epidermal necrolysis associated with allopurinol use. Arch Ophthalmol. 1977;95:1362–4.

    Article  PubMed  CAS  Google Scholar 

  300. Cheriyan S, Patterson R, Greenberger PA, et al. The outcome of Stevens–Johnson syndrome treated with corticosteroids. Allergy Proc. 1995;16:151–5.

    Article  PubMed  CAS  Google Scholar 

  301. Chaidemenos GC, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36:218–21.

    Article  PubMed  CAS  Google Scholar 

  302. Tan SK, Tay YK. Profile and pattern of Stevens–Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol. 2012;92:62–6.

    Article  PubMed  Google Scholar 

  303. Patterson R, Cheriyan S, Greenberger PA. Recurrent dermopathy after remission of Stevens–Johnson syndrome secondary to mild dermal trauma. Allergy Proc. 1995;16:115–8.

    Article  PubMed  CAS  Google Scholar 

  304. Struck MF, Illert T, Schmidt T, et al. Secondary abdominal compartment syndrome in patients with toxic epidermal necrolysis. Burns. 2012;38:562–7.

    Article  PubMed  Google Scholar 

  305. Yun SJ, Choi MS, Piao MS, et al. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis. Dermatology. 2008;217:254–9.

    Article  PubMed  CAS  Google Scholar 

  306. Trautmann A, Klein CE, Kampgen E, et al. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol. 1998;139:1127–8.

    Article  PubMed  CAS  Google Scholar 

  307. Arevalo JM, Lorente JA. Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil. 1999;20:406–10.

    Article  PubMed  CAS  Google Scholar 

  308. Moniz P, Casal D, Mavioso C, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: a 15-year retrospective study. Acta Med Port. 2011;24:59–70.

    PubMed  Google Scholar 

  309. Ziemer M, Kardaun SH, Liss Y, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012;166:575–600.

    Article  PubMed  CAS  Google Scholar 

  310. Davies P, Ryan DW. Stevens–Johnson syndrome managed in the Clinitron bed. Intensive Care Med. 1983;9:87–9.

    Article  PubMed  CAS  Google Scholar 

  311. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19:704–9.

    Article  PubMed  CAS  Google Scholar 

  312. Kelso JM, Keating RM. Successful desensitization for treatment of a fixed drug eruption to allopurinol. J Allergy Clin Immunol. 1996;97:1171–2.

    Article  PubMed  CAS  Google Scholar 

  313. Teraki Y, Shiohara T. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology. 2004;209:29–32.

    Article  PubMed  Google Scholar 

  314. Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens–Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol. 2005;30:600–2.

    Article  PubMed  CAS  Google Scholar 

  315. Ying S, Ho W, Chan HH. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns. 2001;27:372–5.

    Article  PubMed  CAS  Google Scholar 

  316. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26–32.

    Article  PubMed  CAS  Google Scholar 

  317. Fania L, Giannico MI, Fasciani R, et al. Ocular mucous membrane pemphigoid after Lyell syndrome: occasional finding or predisposing event? Ophthalmology. 2012;119:688–93.

    Article  PubMed  Google Scholar 

  318. Sakellariou G, Koukoudis P, Karpouzas J, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs. 1991;14:634–8.

    PubMed  CAS  Google Scholar 

  319. Marra LM, Wunderle RC. Oral presentation of toxic epidermal necrolysis. J Oral Maxillofac Surg. 1982;40:59–61.

    Article  PubMed  CAS  Google Scholar 

  320. Carmona AF, Redondo AD, Pena LO, et al. Toxic epidermal necrolysis treated with cyclosporin A. Med Intensiva. 2011;35:442–5.

    Article  PubMed  Google Scholar 

  321. Bashir S, Shah SM, Babar I. Allopurinol induced Stevens–Johnson syndrome: a case report. J Pak Med Assoc. 2000;50:207–9.

    PubMed  CAS  Google Scholar 

  322. Boffa MJ, Chalmers RJ. Allopurinol-induced toxic pustuloderma. Br J Dermatol. 1994;131:447.

    Article  PubMed  CAS  Google Scholar 

  323. Correia O, Chosidow O, Saiag P, et al. Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology. 1993;186:32–7.

    Article  PubMed  CAS  Google Scholar 

  324. Goldfarb E, Smyth CJ. Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout. Arthritis Rheum. 1966;9:414–23.

    Article  PubMed  CAS  Google Scholar 

  325. Guillaume JC, Roujeau JC, Revuz J, et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell’s syndrome). Arch Dermatol. 1987;123:1166–70.

    Article  PubMed  CAS  Google Scholar 

  326. Hanken I, Schimmer M, Sander CA. Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis. J Dtsch Dermatol Ges. 2010;8:341–6.

    Article  PubMed  Google Scholar 

  327. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9:1617–22.

    Article  PubMed  CAS  Google Scholar 

  328. Lee HJ, Kim HS, Park YM, et al. Fixed drug eruption due to allopurinol: positive oral provocation. Ann Dermatol. 2011;23:S402–3.

    Article  PubMed  Google Scholar 

  329. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99–107.

    Article  PubMed  CAS  Google Scholar 

  330. Lun K, Harley W. Allopurinol-induced pustular eruption: an unusually mild case. Australas J Dermatol. 2002;43:140–3.

    Article  PubMed  Google Scholar 

  331. Nasser M, Bitterman-Deutsch O, Nassar F. Intravenous immunoglobulin for treatment of toxic epidermal necrolysis. Am J Med Sci. 2005;329:95–8.

    Article  PubMed  Google Scholar 

  332. Ooi CG, Walker P, Sidhu SK, et al. Allopurinol induced generalized eosinophilic pustular folliculitis. Australas J Dermatol. 2006;47:270–3.

    Article  PubMed  Google Scholar 

  333. Stratigos JD, Bartsokas SK, Capetanakis J. Further experiences of toxic epidermal necrolysis incriminating allopurinol, pyrazolone and derivatives. Br J Dermatol. 1972;86:564–7.

    Article  PubMed  CAS  Google Scholar 

  334. Thomas J. Dermatologic complications of allopurinol treatment of gout. Rein et Foie. 1969;12:129–33.

    Google Scholar 

  335. Trent JT, Kirsner RS, Romanelli P, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol. 2003;139:39–43.

    Article  PubMed  CAS  Google Scholar 

  336. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490–3.

    Article  PubMed  CAS  Google Scholar 

  337. Yip LW, Thong BY, Tan AW, et al. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye (Lond). 2005;19:846–53.

    Article  CAS  Google Scholar 

  338. Becker D, Enk A, Brauninger W, et al. Granuloma anulare disseminatum as a rare side effect of allopurinol. Hautarzt. 1995;46:343–5.

    Article  PubMed  CAS  Google Scholar 

  339. Hara Y, Yoshioka M, Yoshiki R, et al. Increased human herpes virus 6 DNA detected by real-time PCR in the saliva of two patients with drug-induced hypersensitivity syndrome. Eur J Dermatol. 2012;22:418–9.

    PubMed  Google Scholar 

  340. Pasero G, Riccioni N, Rizzo G. Prime esperienze con un inibitore della xantina-ossidasi (4-idrossi-pirazolo-(3,4-d)-pirimidina; allopurino) nel trattamento di soggetti gottosi con grave compromissione della funzione renale. La Settimana medica. 1966;54:63–8.

    Google Scholar 

  341. Cusido GVI, Aguilar JL. Exantema fijo medicamentoso inducido por alopurinol. Actas Dermo-Sifiliograficas. 1994;85:755–7.

    Google Scholar 

  342. Wolf R, Orion E, Marcos B, et al. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005;23:171–81.

    Article  PubMed  Google Scholar 

  343. Peterson GM, Boyle RR, Francis HW, et al. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol. 1990;39:419–21.

    Article  PubMed  CAS  Google Scholar 

  344. Stuart RA, Gow PJ, Bellamy N, et al. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis. N Z Med J. 1991;104:115–7.

    PubMed  CAS  Google Scholar 

  345. McClintock AD, Egan AJ, Woods DJ, et al. A survey of allopurinol dosage prescribing. N Z Med J. 1995;108:346–7.

    PubMed  CAS  Google Scholar 

  346. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925–34.

    Article  PubMed  Google Scholar 

  347. Smith P, Karlson N, Nair BR. Quality use of allopurinol in the elderly. J Qual Clin Pract. 2000;20:42–3.

    Article  PubMed  CAS  Google Scholar 

  348. Stamp L, Gow P, Sharples K, et al. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med. 2000;30:567–72.

    Article  PubMed  CAS  Google Scholar 

  349. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646–50.

    PubMed  CAS  Google Scholar 

  350. Athisakul S, Wangkaew S, Louthrenoo W. Inappropriate prescription of allopurinol in a teaching hospital. J Med Assoc Thai. 2007;90:889–94.

    PubMed  Google Scholar 

  351. Atzori L, Pinna AL, Mantovani L, et al. Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department—Cagliari University (Italy). J Eur Acad Dermatol Venereol. 2012;26:1424–30.

    Article  PubMed  CAS  Google Scholar 

  352. Jung JW, Kim MH, Song WJ, et al. HLA-B58 does not increase allopurinol hypersensitivity among patients with hematologic malignancy. XXII World Allergy Congress; 2012 (4–8 December 2011); Cancun, Mexico: World Allergy Organization; 2012. p. S98.

  353. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57:545–9.

    Article  PubMed  CAS  Google Scholar 

  354. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis. 2009;68:892–7.

    Article  PubMed  CAS  Google Scholar 

  355. Stamp LK, O’Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63:412–21.

    Article  PubMed  CAS  Google Scholar 

  356. Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966;15:863–80.

    Article  PubMed  CAS  Google Scholar 

  357. Hande K, Reed E, Chabner B. Allopurinol kinetics. Clin Pharmacol Ther. 1978;23:598–605.

    PubMed  CAS  Google Scholar 

  358. Rodnan GP, Robin JA, Tolchin SF, et al. Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA. 1975;231:1143–7.

    Article  PubMed  CAS  Google Scholar 

  359. Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987;26:445–9.

    Article  PubMed  CAS  Google Scholar 

  360. Panomvana D, Sripradit S, Angthararak S. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol. 2008;14:6–11.

    Article  PubMed  Google Scholar 

  361. Stamp LK, Barclay ML, O’Donnell JL, et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther. 2011;90:392–8.

    Article  PubMed  CAS  Google Scholar 

  362. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50:937–43.

    Article  PubMed  Google Scholar 

  363. Bellamy N, Brooks PM, Emmerson BT, et al. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust. 1989;151:531–2 535–7.

    PubMed  CAS  Google Scholar 

  364. Mikuls TR, Farrar JT, Bilker WB, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford). 2005;44:1038–42.

    Article  CAS  Google Scholar 

  365. Hall AP, Barry PE, Dawber TR, et al. Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med. 1967;42:27–37.

    Article  PubMed  CAS  Google Scholar 

  366. Rosenfeld JB. Effect of allopurinol administration on serum GFR in normotensive and hypertensive hyperuricemia subjects. Adv Exp Med Biol. 1974;41B:581–96.

    Article  Google Scholar 

  367. Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67:74–82.

    Article  PubMed  CAS  Google Scholar 

  368. Yu TF, Berger L, Dorph DJ, et al. Renal function in gout. V. Factors influencing the renal hemodynamics. Am J Med. 1979;67:766–71.

    Article  PubMed  CAS  Google Scholar 

  369. McGill NW. Gout and other crystal arthropathies. Med J Aust. 1997;166:33–8.

    PubMed  CAS  Google Scholar 

  370. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail. 2009;2:556–62.

    Article  PubMed  CAS  Google Scholar 

  371. Pater C. Hyperuricemia and hypertension: a causal relationship ignored for all too long. Curr Hypertens Rev. 2011;7:41–53.

    Article  CAS  Google Scholar 

  372. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–90.

    Article  PubMed  CAS  Google Scholar 

  373. Johnson RJ, Feig DI, Herrera-Acosta J, et al. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005;45:18–20.

    Article  PubMed  CAS  Google Scholar 

  374. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol. 2005;16:1909–19.

    Article  PubMed  CAS  Google Scholar 

  375. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36:1072–8.

    Article  PubMed  CAS  Google Scholar 

  376. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75(Suppl 5):S13–6.

    Article  PubMed  Google Scholar 

  377. Gaffo AL, Saag KG. Drug treatment of hyperuricemia to prevent cardiovascular outcomes: are we there yet? Am J Cardiovasc Drugs. 2012;12:1–6.

    Article  PubMed  CAS  Google Scholar 

  378. See LC, Kuo CF, Chuang FH, et al. Hyperuricemia and metabolic syndrome: associations with chronic kidney disease. Clin Rheumatol. 2011;30:323–30.

    Article  PubMed  Google Scholar 

  379. Goncalves JP, Oliveira A, Severo M, et al. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine. 2012;41:450–7.

    Article  PubMed  CAS  Google Scholar 

  380. Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res. 2006;37:883–9.

    Article  PubMed  CAS  Google Scholar 

  381. Avram Z, Krishnan E. Hyperuricaemia: where nephrology meets rheumatology. Rheumatology. 2008;47:960–4.

    Article  PubMed  CAS  Google Scholar 

  382. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–9.

    Article  PubMed  CAS  Google Scholar 

  383. Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol. 2006;33:104–9.

    PubMed  Google Scholar 

  384. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961;55:179–92.

    Article  PubMed  CAS  Google Scholar 

  385. Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008;35:498–501.

    PubMed  Google Scholar 

  386. Kitts A, Feolo M, Helmberg W. Allele and haplotype frequencies. dbMHC anthropology search results (HLA-B*58:01:01). National Center for Biotechnology Information (NCBI). http://www.ncbi.nlm.nih.gov/projects/gv/mhc/ihwg.cgi. Accessed 14 Dec 2012.

  387. Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica. 1989;179:32–3.

    Article  PubMed  CAS  Google Scholar 

  388. Cristallo AF, Schroeder J, Citterio A, et al. A study of HLA class I and class II 4-digit allele level in Stevens–Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011;38:303–9.

    Article  PubMed  CAS  Google Scholar 

  389. Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21:303–7.

    Article  PubMed  CAS  Google Scholar 

  390. Phillips EJ, Chung WH, Mockenhaupt M, et al. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011;127:S60–6.

    Article  PubMed  CAS  Google Scholar 

  391. Somkrua R, Eickman EE, Saokaew S, et al. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.

    Article  PubMed  CAS  Google Scholar 

  392. Somkrua R, Chaiyakunapruk N, Tassaneeyakul W. What cost of HLA-B*5801 genotyping would be cost-effective for the prevention of allopurinol-induced Stevens–Johnson syndrome/Toxic Epidermal Necrolysis in Thailand: analyses using a decision-analytic model. Value Health. 2010;13:A564–5.

    Article  Google Scholar 

  393. Yeo SI. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region. Int J Rheum Dis. 2013.

  394. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403–6.

    PubMed  Google Scholar 

  395. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582–7.

    PubMed  Google Scholar 

  396. Singh JA, Hodges JS, Toscano JP, et al. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57:822–9.

    Article  PubMed  Google Scholar 

  397. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35.

    Article  PubMed  Google Scholar 

  398. Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69:1305–9.

    Article  PubMed  Google Scholar 

  399. Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol. 2004;10:308–14.

    Article  PubMed  Google Scholar 

  400. Keenan RT, O’Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155–63.

    Article  PubMed  Google Scholar 

  401. Fuldeore MJ, Riedel AA, Zarotsky V, et al. Chronic kidney disease in gout in a managed care setting. BMC Nephrol. 2011;12:36.

    Article  PubMed  Google Scholar 

  402. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(679–87):e1.

    Google Scholar 

  403. Sharpe CR. A case-control study of alcohol consumption and drinking behaviour in patients with acute gout. Can Med Assoc J. 1984;131:563–7.

    PubMed  CAS  Google Scholar 

  404. Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004–7.

    Article  PubMed  CAS  Google Scholar 

  405. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445–51.

    Article  PubMed  CAS  Google Scholar 

  406. Tikly M, Bellingan A, Lincoln D, et al. Risk factors for gout: a hospital-based study in urban black South Africans. Rev Rhum Engl Ed. 1998;65:225–31.

    PubMed  CAS  Google Scholar 

  407. McGill NW. Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol. 2000;14:445–60.

    Article  PubMed  CAS  Google Scholar 

  408. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29:1350–5.

    PubMed  CAS  Google Scholar 

  409. Mandell BF. Hyperuricemia and gout: a reign of complacency. Cleve Clin J Med. 2002;69:589–90 92–3.

    Article  PubMed  Google Scholar 

  410. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67:960–6.

    Article  PubMed  CAS  Google Scholar 

  411. Shiohara T, Iijima M, Ikezawa Z, et al. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156:1083–4.

    Article  PubMed  CAS  Google Scholar 

  412. Pritchett JC, Nanau RM, Neuman MG. The link between hypersensitivity syndrome reaction development and human herpes virus-6 reactivation. Int J Hepatol. 2012;2012:723062.

    PubMed  Google Scholar 

  413. Shiohara T, Kano Y, Takahashi R, et al. Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management. Chem Immunol Allergy. 2012;97:122–38.

    Article  PubMed  Google Scholar 

  414. Criado PR, Criado RF, Avancini Jde M, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol. 2012;87:435–49.

    Article  PubMed  Google Scholar 

  415. Hirahara K, Kano Y, Mitsuyama Y, et al. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions. Clin Exp Dermatol. 2010;35:863–8.

    Article  PubMed  CAS  Google Scholar 

  416. Mockenhaupt M. Allopurinol is the most frequent cause of Stevens–Johnson syndrome and toxic epidermal necrolysis. Expert Rev Dermatol. 2012;7:213–5.

    Article  CAS  Google Scholar 

  417. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.

    Article  PubMed  CAS  Google Scholar 

  418. de Klerk E, van der Heijde D, Landewe R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30:44–54.

    PubMed  Google Scholar 

  419. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31:1575–81.

    PubMed  Google Scholar 

  420. Solomon DH, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67:609–13.

    Article  PubMed  CAS  Google Scholar 

  421. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum. 2009;38:396–402.

    Article  PubMed  Google Scholar 

  422. Bull PW, Scott JT. Intermittent control of hyperuricaemia in the treatment of gout. Adv Exp Med Biol. 1989;253A:251–5.

    Article  PubMed  CAS  Google Scholar 

  423. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11:S435–42 quiz S65–8.

    PubMed  Google Scholar 

  424. Harrold LR, Mazor KM, Velten S, et al. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010;6:263–71.

    Article  PubMed  Google Scholar 

  425. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71:1490–5.

    Article  PubMed  Google Scholar 

  426. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59:809–20.

    Article  PubMed  CAS  Google Scholar 

  427. Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62:1439–44.

    Article  PubMed  CAS  Google Scholar 

  428. Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol. 2007;7:299–303.

    PubMed  Google Scholar 

  429. Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol. 2010;10:291–6.

    Article  PubMed  CAS  Google Scholar 

  430. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol. 2005;152:968–74.

    Article  PubMed  CAS  Google Scholar 

  431. Andrade P, Brinca A, Goncalo M. Patch testing in fixed drug eruptions: a 20-year review. Contact Dermat. 2011;65:195–201.

    Article  Google Scholar 

  432. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005;209:209–16.

    Article  PubMed  CAS  Google Scholar 

  433. Waton J, Trechot P, Loss-Ayav C, et al. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions. Br J Dermatol. 2009;160:786–94.

    Article  PubMed  CAS  Google Scholar 

  434. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions—new concepts. Clin Exp Allergy. 2007;37:989–99.

    Article  PubMed  CAS  Google Scholar 

  435. Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin N Am. 2010;94:711–25 x.

    Article  PubMed  Google Scholar 

  436. Kim SC, Newcomb C, Margolis D, et al. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken). 2012.

  437. Ryu HJ, Song R, Kim HW, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol. 2012.

  438. Riedel MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68:1781–91.

    Google Scholar 

  439. Rieder MJ. Immune mediation of hypersensitivity adverse drug reactions: implications for therapy. Expert Opin Drug Saf. 2009;8:331–43.

    Article  PubMed  CAS  Google Scholar 

  440. Harr T, French LE. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.

    Article  PubMed  Google Scholar 

  441. Worswick S, Cotliar J. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermatol Ther. 2011;24:207–18.

    Article  PubMed  Google Scholar 

  442. Michaels B. The role of systemic corticosteroid therapy in erythema multiforme major and Stevens–Johnson syndrome: a review of past and current opinions. J Clin Aesthet Dermatol. 2009;2:51–5.

    PubMed  Google Scholar 

  443. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33–6.

    Article  PubMed  CAS  Google Scholar 

  444. Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81–8.

    Article  PubMed  CAS  Google Scholar 

  445. Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25:246–55.

    Article  PubMed  Google Scholar 

  446. Pasic S. Intravenous immunoglobulin in toxic epidermal necrolysis. Int J Dermatol. 2006;45:1117–8.

    Article  PubMed  Google Scholar 

  447. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens–Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics. 2003;112:1430–6.

    Article  PubMed  Google Scholar 

  448. Al-Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol. 2004;43:847–51.

    Article  PubMed  CAS  Google Scholar 

  449. Tan AW, Thong BY, Yip LW, et al. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol. 2005;32:1–6.

    PubMed  CAS  Google Scholar 

  450. Mangla K, Rastogi S, Goyal P, et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol. 2005;71:398–400.

    Article  PubMed  Google Scholar 

  451. Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007;33:452–9.

    Article  PubMed  Google Scholar 

  452. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33–40.

    Article  PubMed  Google Scholar 

  453. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens–Johnson syndrome: our current understanding. Int Immunopharmacol. 2006;6:543–9.

    Article  PubMed  CAS  Google Scholar 

  454. Trent J, Halem M, French LE, et al. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin Cutan Med Surg. 2006;25:91–3.

    Article  PubMed  CAS  Google Scholar 

  455. Momin SB. Review of intravenous immunoglobulin in the treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis. J Clin Aesthet Dermatol. 2009;2:51–8.

    PubMed  Google Scholar 

  456. Ferguson JC, Carr RT, Chang EW, et al. Evaluation of endotracheal tube safety for CO2 laser resurfacing. Laryngoscope. 2002;112:1239–42.

    Article  PubMed  Google Scholar 

  457. Aronson JK. Anecdotes as evidence. BMJ. 2003;326:1346.

    Article  PubMed  Google Scholar 

  458. Kelly WN. The quality of published adverse drug event reports. Ann Pharmacother. 2003;37:1774–8.

    Article  PubMed  Google Scholar 

  459. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.

    Article  PubMed  Google Scholar 

  460. Loke YK, Price D, Derry S, et al. Case reports of suspected adverse drug reactions—systematic literature survey of follow-up. BMJ. 2006;332:335–9.

    Article  PubMed  Google Scholar 

  461. Impicciatore P, Mucci M. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database. Drug Saf. 2010;33:765–73.

    Article  PubMed  Google Scholar 

  462. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf. 2007;16:581–7.

    Article  PubMed  Google Scholar 

  463. Longmore JM, Wilkinson IB, Rajagopalan SR. Oxford handbook of clinical medicine. 6th ed. New York: Oxford University Press; 2004.

    Google Scholar 

Download references

Acknowledgments

The research was supported by an Arthritis Australia National Research grant, National Health and Medical Research Council (NH&MRC) Program Grant 568612, and the Lexy Davies Bequest.

Sheena N. Ramasamy, Cameron S. Korb-Wells, Diluk R.W. Kannangara, Myles W.H. Smith, Nan Wang, Darren M. Roberts, Garry G. Graham, Kenneth M. Williams and Richard O. Day declare that they have no competing interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Richard O. Day.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramasamy, S.N., Korb-Wells, C.S., Kannangara, D.R.W. et al. Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012. Drug Saf 36, 953–980 (2013). https://doi.org/10.1007/s40264-013-0084-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-013-0084-0

Navigation